Immatics Holds $521.5M Cash, Eyes 2026 Phase 3 SUPRAME Analyses for 2027 Launch
Immatics holds $521.5M in cash as of March 31, 2026, and expects interim and final Phase 3 SUPRAME analyses of anzu-cel in 2026 ahead of a planned 2027 launch. Immatics expects multiple 2026 readouts including IMA203CD8 and IMA402 data, plus launch of a PRAME TCR bispecific combination trial in sqNSCLC.
1. Financial Position
Immatics reported $521.5 million in cash and cash equivalents as of March 31, 2026, providing funding for operations into 2028 under current projections.
2. Phase 3 SUPRAME Trial Progress
The global, randomized SUPRAME trial is evaluating anzu-cel versus investigator’s choice in advanced cutaneous melanoma, with blinded independent central review-assessed progression-free survival as the primary endpoint and interim and final analyses expected in 2026.
3. 2026 Clinical Readouts
Multiple key data sets are slated for 2026 across four clinical-stage programs, including Phase 1 second-generation PRAME cell therapy IMA203CD8 results at ASCO, IMA402 monotherapy and checkpoint inhibitor combination data, and initiation of a PRAME TCR bispecific combination trial in sqNSCLC mid-year.
4. Development and Commercialization Plans
Immatics plans a BLA submission for anzu-cel in the first half of 2027, a Phase 2 uveal melanoma cohort to support label expansion, and a commercial launch in the second half of 2027.